Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||BRAF K601N|
|Gene Variant Detail|
|Relevant Treatment Approaches||MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor LY3009120|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF K601N||Advanced Solid Tumor||resistant||Vemurafenib||Preclinical - Cell culture||Actionable||In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).||26343582|
|BRAF K601N||hematologic cancer||sensitive||LY3009120||LY3009120||Preclinical - Cell culture||Actionable||In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).||26732095|
|BRAF K601N||lung non-small cell carcinoma||no benefit||Vemurafenib||Case Reports/Case Series||Actionable||In a Phase II trial, Zelboraf (vemurafenib) treatment did not result in response in the cohort of 15 non-small cell lung cancer patients with non-V600 BRAF mutations, which included 2 patients harboring BRAF K601N, and enrollment in this cohort was discontinued (PMID: 31959346; NCT02304809).||31959346|
|BRAF K601N||chronic lymphocytic leukemia||sensitive||PLX8394||Preclinical - Cell culture||Actionable||In a preclinical study, PLX8394 treatment inhibited Erk signaling and reduced proliferation of chronic lymphocytic leukemia cells harboring BRAF K601N in culture (PMID: 30559419).||30559419|
|BRAF K601N||lung non-small cell carcinoma||predicted - sensitive||LTT462 + LXH 254||Case Reports/Case Series||Actionable||In a Phase Ib trial, LTT462 and LXH 254 combination therapy was well tolerated and resulted in an unconfirmed partial response (PR) in 4% (2/49) and stable disease (SD) in 33% (16/49) of patients with advanced or metastatic KRAS- or BRAF-mutant non-small cell lung cancer, with 1 patient harboring BRAF K601N achieving an unconfirmed PR (Ann Oncol 31 (suppl 4):S881-S882; NCT02974725).||detail...|